After finishing at $9.37 in the prior trading day, Voyager Therapeutics Inc (NASDAQ: VYGR) closed at $9.06, down -3.31%. In other words, the price has decreased by -$0.31 from its previous closing price. On the day, 590736 shares were traded.
Ratios:
Our goal is to gain a better understanding of VYGR by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.59. For the most recent quarter (mrq), Quick Ratio is recorded 4.96 and its Current Ratio is at 4.96. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 07, 2024, initiated with a Buy rating and assigned the stock a target price of $16.
On January 02, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $14.
On May 10, 2023, Truist started tracking the stock assigning a Buy rating and target price of $18.Truist initiated its Buy rating on May 10, 2023, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 21 ’24 when Sandrock Alfred sold 13,033 shares for $7.46 per share. The transaction valued at 97,226 led to the insider holds 334,954 shares of the business.
Swartz Robin sold 3,966 shares of VYGR for $29,547 on Feb 21 ’24. The Chief Operating Officer now owns 118,361 shares after completing the transaction at $7.45 per share. On Feb 21 ’24, another insider, PFREUNDSCHUH PETER P., who serves as the Chief Financial Officer of the company, sold 3,764 shares for $7.46 each. As a result, the insider received 28,079 and left with 175,669 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 508.80M and an Enterprise Value of 298.21M. As of this moment, Voyager’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.97 while its Price-to-Book (P/B) ratio in mrq is 1.69. Its current Enterprise Value per Revenue stands at 1.19 whereas that against EBITDA is 2.36.
Stock Price History:
Over the past 52 weeks, VYGR has reached a high of $14.34, while it has fallen to a 52-week low of $6.06. The 50-Day Moving Average of the stock is 8.18, while the 200-Day Moving Average is calculated to be 8.74.
Shares Statistics:
The stock has traded on average 823.77K shares per day over the past 3-months and 904.37k shares per day over the last 10 days, according to various share statistics. A total of 44.04M shares are outstanding, with a floating share count of 42.78M. Insiders hold about 21.22% of the company’s shares, while institutions hold 48.33% stake in the company. Shares short for VYGR as of Feb 15, 2024 were 2.15M with a Short Ratio of 2.61, compared to 1.81M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.86% and a Short% of Float of 4.59%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.46 for the current quarter, with a high estimate of -$0.4 and a low estimate of -$0.52, while EPS last year was $2.94. The consensus estimate for the next quarter is -$0.52, with high estimates of -$0.35 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$0.6 and -$2.9 for the fiscal current year, implying an average EPS of -$1.89. EPS for the following year is -$1.87, with 7 analysts recommending between $0.15 and -$4.18.
Revenue Estimates
6 analysts predict $8.22M in revenue for the current quarter. It ranges from a high estimate of $10M to a low estimate of $5M. As of the current estimate, Voyager Therapeutics Inc’s year-ago sales were $150.48M, an estimated decrease of -94.50% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $90.14M, while the lowest revenue estimate was $5M, resulting in an average revenue estimate of $36.62M. In the same quarter a year ago, actual revenue was $250.01M, down -85.40% from the average estimate.
